A Study of T-DXd for the Treatment of Solid Tumors Harboring HER2 Activating Mutations
A Study of T-DXd for the Treatment of Solid Tumors Harboring HER2 Activating Mutations
Active, not recruiting · NCT04639219 · Registry updated 2026-03-23Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study of T-DXd for the Treatment of Solid Tumors Harboring HER2 Activating Mutations | Neoplasm Metastasis, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, neoplasm | Active, not recruiting | Phase 2 | 2026-03-23 | NCT04639219 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| AstraZeneca | 806 |
| Daiichi Sankyo Co., Ltd. | 14 |
0 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| No products are listed yet. | |||